Merck KGaA Profit Beats Estimates on Cost-Cutting

REPLAY VIDEO
Your next video will start in
Pause
  • Info

  • Comments

May 14 (Bloomberg) -- Merck KGaA, the German maker of cancer drug Erbitux, said first-quarter profit rose on higher-than-expected savings from a reorganization program, and forecast it will achieve 2014 targets a year ahead of schedule. Mark Barton reports on Bloomberg Television's "Countdown." (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change